Sign In
Register
eISSN:2278-5299

International Journal of Latest Research in Science and Technology

DOI:10.29111/ijlrst   ISRA Impact Factor:3.35

A News Letter Sign UP!
FUNCTIONAL CELL-PROLIFERATION AND DIFFERENTIATION BY SYSTEM MODELING FOR CELL THERAPY

Research Paper Open Access

International Journal of Latest Research in Science and Technology Vol.4 Issue 2, pp 180-187,Year 2015

FUNCTIONAL CELL-PROLIFERATION AND DIFFERENTIATION BY SYSTEM MODELING FOR CELL THERAPY

Biaoru Li,Hongliang Hu, Jianqing Ding,David Yan and Liming Yang

Correspondence should be addressed to :

Received : 21 April 2015; Accepted : 28 April 2015 ; Published : 30 April 2015

Share
Download 125
View 177
Article No. 10516
Abstract

When primary-cells including non-modified and modified human cells which are used to produce a special substance are infused into patients, it would be defined as cell therapy. A good cell performance with its good proliferation model for cell engineering and cell therapy should maintain its characterization and efficacy with ethical acceptation and safe application. Because efficacy of cell therapy maybe will be decreased in vivo special microenvironment after infusion, moreover because safety of cell therapy would be challenged by DNA genetically modified human cell, a functional induction/inhibition of some genes expressions used in the primary-cell growth without DNA genetic modification has been increasingly reported. Here, the cell therapy of cell engineering based on system modeling for a special function and/or still retaining a special function in vivo microenvironment is called as functional cell-therapy. Nowadays, following research and development (R&D) of primary-cell engineering techniques and system modeling with this computational simulation performance, the novel techniques of primary-cell culture based on system biology will be progressively studied for stem cell which scientists designed and induced into special functional cells for regeneration medicine or for quiescent T-cell which oncologists apply for personalized immunotherapy for tumor disease.

Key Words   
Primary cell culture, cell therapy, T-cell, stem cell, genomic analysis, system mo

Copyright
References
  1. Berggren JR, Tanner CJ, Houmard JA. Primary cell cultures in the study of human muscle metabolism. Exerc Sport Sci Rev. 2007 Apr;35(2):56-61.
  2. Brevini TA, Antonini S, Cillo F, Crestan M, Gandolfi F. Porcine embryonic stem cells: Facts, challenges and hopes. 2007 Sep 1;68Suppl 1:S206-13.
  3. Teng M, Geng Z, Huang L, Zhao X. Stem cell transplantation in cardiovascular disease: an update. J Int Med Res.2012;40(3):833-8.
  4. Li Y, Tsai YT, Hsu CW, Erol D, Yang J, Wu WH, Davis RJ, Egli D, Tsang SH. Long-term safety and efficacy of human-induced pluripotent stem cell (iPS) grafts in a preclinical model of retinitis pigmentosa. Mol Med. 2012 Dec 6;18:1312-9.
  5. Hughes CS, Radan L, Betts D, Postovit LM, Lajoie GA. Proteomic analysis of extracellular matrices used in stem cell culture. 2011 Oct;11(20):3983-91.
  6. Kuettner H. Verimpfunganstelle der transplantation hochwertigerorgane. Zentralblatt fur Chirugie 1:390-397, 1912., as cited in Popov IM and others. Journal of the International Academy of Preventive Medicine. 40:74-82.
  7. KUHNAU WW. Pituitary fresh cell implantation as endocrine stimulation. Med Klin (Munich). 1955 Jul 15;50(28):1187-9.
  8. Takata K, Kitamura Y. Molecular approaches to the treatment, prophylaxis, and diagnosis of Alzheimer's disease: tangle formation, amyloid-β, and microglia in Alzheimer's disease. J Pharmacol Sci.2012;118(3):331-7.
  9. Foreman PJ, Ward J. An evaluation of cell therapy in Down syndrome. Australian PaediatricJournal. 23:151-156.
  10. Howard Levy vs Dr. Gabriel Cousens, No. 333704, Superior Court for the State of Arizona in and for the County of Pima, Plaintiff's initial disclosure statement. 1999, filed Oct 13.
  11. Wislet-Gendebien S, Laudet E, Neirinckx V, Rogister B. Adult bone marrow: which stem cells for cellular therapy protocols in neurodegenerative disorders?Biomed Biotechnol. 2012;2012:601560.
  12. Dausset J. The HLA complex. 3. Implications in transplantation and transfusion. NouvPresse Med. 1976 May 29;5(22):1413-6.
  13. Larijani B, Esfahani EN, Amini P, Nikbin B, Alimoghaddam K, Amiri S, Malekzadeh R, Yazdi NM, Ghodsi M, Dowlati Y, Sahraian MA, Ghavamzadeh A. Stem cell therapy in treatment of different diseases. Acta Med Iran.2012;50(2):79-96.
  14. Dickerson JB. Provenge: revolutionary technology or ethical bust? Hum Vaccin.2011 Apr;7(4):477-80.
  15. Busca A. The use of monoclonal antibodies for the treatment of graft-versus-host disease following allogeneic stem cell transplantation. Expert OpinBiolTher. 2011 Jun;11(6):687-97
  16. Barriga F, Wietstruck MA. Search for unrelated donor umbilical cord blood units for allogeneic stem cell transplantation: results in two time periods. Transplant Proc. 2007 Apr;39(3):629-30.
  17. Zhdanov RI, Podobed OV, Vlassov VV. Cationic lipid-DNA complexes-lipoplexes-for gene transfer and therapy. 2002 Nov;58(1):53-64.
  18. Li B, Ding J, Larson A, Song S. Tumor tissue recycling--a new combination treatment for solid tumors: experimental and preliminary clinical research. In Vivo. 1999 Sep-Oct;13(5):433-8.
  19. Stein JL, de la Torre-Ubieta L, Tian Y, Parikshak NN, Hernández IA, Marchetto MC, Baker DK, Lu D, Hinman CR, Lowe JK, Wexler EM, Muotri AR, Gage FH, Kosik KS, Geschwind DHA quantitative framework to evaluate modeling of cortical development by neural stem cells. 2014 Jul;83(1):69-86.
  20. Thiele I, Bernhard P. A protocol for generating a high-quality genome-scale metabolic reconstruction. Nature Protocols. 2010; 5: 93–121.
  21. Shi M, Wu M, Pan P, Zhao R. Network-based sub-network signatures unveil the potential for acute myeloid leukemia therapy. 2014: DOI: 10.1039/C4MB00440J.
  22. Lv S, Xu Y, Chen X, Li Y, Li R, Wang Q, Li X, Su B. Prioritizing cancer therapeutic small molecules by integrating multiple OMICS datasets. 2012 Oct;16(10):552-9.
  23. Ratcliffe E, Thomas RJ, Williams DJ. Current understanding and challenges in bioprocessing of stem cell-based therapies for regenerative medicine. Br Med Bull. 2011;100:137-55.
  24. Brindley D, Natasha D, Emily CS, Chris M, David WS and Jon AR. Peak Serum: Implications for Cell Therapy Manufacturing. Regenerative Medicine. 2012 Jan; 7 (1): 7–13.
  25. McCoy R, Hoare M, Ward S. Ultra scale-down studies of the effect of shear on cell quality; Processing of a human cell line for cancer vaccine therapy. 2009 Sep-Oct;25(5):1448-58.
  26. Pahwa R, Jaggaiahgari S, Pahwa S, Inverardi L, Tzakis A, Ricordi C. Isolation and expansion of human natural T regulatory cells for cellular therapy. J Immunol Methods.2010 Dec 15;363(1):67-79.
  27. Takeuchi S. A new look at the history of tumor immunotherapy--for its fruitful future through overcoming the widespread cynicism. Hum Cell. 1996 Mar;9(1):1-10.
  28. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. 1986 Sep 19;233(4770):1318-21.
  29. Ortegel JW, Staren ED, Faber LP, Warren WH, Braun DP. Modulation of tumor-infiltrating lymphocyte cytolytic activity against human non-small cell lung cancer. Lung Cancer. 2002 Apr;36(1):17-25.
  30. Leong SP. Immunotherapy of malignant melanoma. SurgClin North Am.1996 Dec;76(6):1355-81.
  31. Lippman SM, Spier CM, Miller TP, Slymen DJ, Rybski JA, Grogan TM. Tumor-infiltrating T-lymphocytes in B-cell diffuse large cell lymphoma related to disease course. Mod Pathol.1990 May;3(3):361-7.
  32. Li B and Tong SQ, Higher activity TIL Isolation and Analysis. Immunological Journal. 1994; 10(1): 44-47.
  33. Li B, Tong SQ, Zhang XH, Lu J, Gu QL, Lu DY. A new experimental and clinical approach of combining usage of highly active tumor-infiltrating lymphocytes and highly sensitive antitumor drugs for the advanced malignant tumor. Chin Med J (Engl). 1994 Nov;107(11):803-7.
  34. Wang Z, Hu H, Zheng J, Li B. Gene expression and pathway analysis of quiescent CD8+ T Cells from liver cancer, liver sinusoid and peripheral blood -- study on toxicogenomics and prevention targeting. IEEE International Symposium on BioInformatics and BioEngineering(BIBE) 2011. 2011:72-77.
  35. TAO J, ZHANG G, DING J, Li B, Tong SQ. Experimental Study on Human Tumor Necrosis Factor α Genes Delivery via Receptor-mediated Endocytosis. Shanghai Second Medical University 1: 3-12.
  36. Ding J, Qian, G, Li B, Tong SQ, Zhang XH, Lu J, Gu QL, Lu DY and Chen SS. Primary research and application by TNF gene transducing into TIL.Chin J of Cancer Biotherapy. 1995 Jan; 2(1):11-15.
  37. Zhang W, Ding J, Qu Y, Hu H, Lin M, Datta A, Larson A, Liu GE, Li B. Genomic expression analysis by single-cell mRNA differential display of quiescent CD8 T cells from tumour-infiltrating lymphocytes obtained from in vivo liver tumours. 2009 May;127(1):83-90.
  38. Owen MR, Sherratt JA. Pattern formation and spatiotemporal irregularity in a model for macrophage-tumour interactions. J Theor Biol. 1997 Nov 7;189(1):63-80.
  39. Caras I, Tucureanu C, Lerescu L, Pitica R, Melinceanu L, Neagu S, Salageanu A. Influence of tumor cell culture supernatants on macrophage functional polarization: in vitro models of macrophage-tumor environment interaction. 2011 Sep-Oct;97(5):647-54.
  40. Wada N, Zaki MA, Hori Y, Hashimoto K, Tsukaguchi M, Tatsumi Y, Ishikawa J, Tominaga N, Sakoda H, Take H, Tsudo M, Kuwayama M, Morii E, Aozasa K; Osaka Lymphoma Study Group. Tumour-associated macrophages in diffuse large B-cell lymphoma: a study of the Osaka Lymphoma Study Group. 2012 Jan;60(2):313-9.
To cite this article

Biaoru Li,Hongliang Hu, Jianqing Ding,David Yan and Liming Yang , " Functional Cell-proliferation And Differentiation By System Modeling For Cell Therapy ", International Journal of Latest Research in Science and Technology . Vol. 4, Issue 2, pp 180-187 , 2015

Responsive image

MNK Publication was founded in 2012 to upholder revolutionary ideas that would advance the research and practice of business and management. Today, we comply with to advance fresh thinking in latest scientific fields where we think we can make a real difference and growth now also including medical and social care, education,management and engineering.

Responsive image

We offers several opportunities for partnership and tie-up with individual, corporate and organizational level. We are working on the open access platform. Editors, authors, readers, librarians and conference organizer can work together. We are giving open opportunities to all. Our team is always willing to work and collaborate to promote open access publication.

Responsive image

Our Journals provide one of the strongest International open access platform for research communities. Our conference proceeding services provide conference organizers a privileged platform for publishing extended conference papers as journal publications. It is deliberated to disseminate scientific research and to establish long term International collaborations and partnerships with academic communities and conference organizers.